Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in Children with ADHD and/or Reading Disorder
NCT00191906Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), reading disorder, sponsored by Eli Lilly and Company. Started Apr 2005; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)reading disorder
Beyond the preview
Go deeper on NCT00191906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191906.